Clostridium difficile-associated colitis: literature review, case report

Authors

  • Y.M. Stepanov SI “Institute of Gastroenterology of the NAMS of Ukraine”, Dnipro, Ukraine
  • E.V. Simonova SI “Institute of Gastroenterology of the NAMS of Ukraine”, Dnipro, Ukraine
  • I.Y. Budzak SE “Dnipropetrovsk Medical Academy of MH of Ukraine”, Dnipro, Ukraine
  • I.N. Коnonov SE “Dnipropetrovsk Medical Academy of MH of Ukraine”, Dnipro, Ukraine

DOI:

https://doi.org/10.22141/2308-2097.54.3.2020.211739

Keywords:

Clostridium difficile infection, Clostridium difficile-associated colitis, pseudomembranous colitis, literature review, etio­logy, epidemiology, diagnosis, treatment, clinical case

Abstract

The article presents modern ideas about Clostridium difficile (C. difficile) infections: the modern classification is given, the questions of epidemiology, etiology, the pathogenesis of intestinal disorders, the clinical aspects of this disease, as well as laboratory, endoscopic, morphological manifestations are considered. Mo­dern international approaches to the treatment of C. difficile infection are presented. C. difficile-associated colitis is a disease that develops with an intestinal microbiome disorder with excessive colonization of C. difficile, the toxins of which cause inflammation and damage to the colon mucosa and diarrhea. The antibiotics intake leads to the inhibition of endogenous microflora and propagation of C. difficile due to spore-forming plasmids; after drug withdrawal spores go into the vegetative form of bacteria and begin to produce toxins; as a result of damage to the endothelium, extensive inflammatory changes in the mucous membrane of the colon, patches of necrosis are formed on the surface of the epithelium with the formation of pseudomembranes (exudative plaques). The Clostridial infection leads to a wide range of clinical manifestations from an asympto­matic course, moderate, uncomplicated diarrhea to life-threatening pseudomembranous colitis — a severe clinical form of C. difficile-associated colitis caused by the toxigenic form of C. difficile, a cha­racteristic feature of which are fibrinous deposits on the colon mucosa (pseudomembranes) identified by endoscopic exa­mination. The gold standard and the most informative method for verifying a diagnosis is the detection of C. difficile toxins in feces. In the diagnosis of C. difficile-associated colitis, an important role belongs to the assessment of laboratory parameters, endoscopic and morphological examinations. When pseudomembranous colitis is diagnosed, treatment should be started immediately. The first step is to cancel the antibiotic that has caused diarrhea. The necessary part of standard therapy for patients with C. difficile-associated colitis is an antibiotic therapy, which limits C. difficile colonization of the intestines and has an anti-inflammatory effect. C. difficile is most sensitive to vancomycin and metronidazole. The enteral administration of antibiotics is necessary since their parenteral administration in the intestine does not always create a sufficient concentration of antibiotics, and therefore, complete liquidation of C. difficile may not occur. The article shows and analyzes the clinical case of the patient with this disease who was treated at the Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine.

Downloads

Download data is not yet available.

References

Ivashkin VT, Shifrin OS, Tertychny AS. Clostridium difficile-associated disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(6):5-17. (in Russian).

Lysiuk YuS, Kohut LM, Romanchak DL, Voitovych OV. Pseudomembranous colitis - the practical aspects of diagnosis and treatment (brief literature review). Hospital Surgery. Journal named by LYa Kovalchuk. 2017;(4):96-102. (in Ukrainian).

Lysiuk YuS, Andriuschenko VP, Kohut LM, Hirniak OT, Lysiuk IS. Pseudomembranous colitis: multidisciplinary principles of prevention, diagnosis and treatment policy. Scientific Herald of Uzhhorod University. Series Medicine. 2016;(54):105-111. (in Ukrainian).

McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085.

Sartelli M, Di Bella S, McFarland LV, et al. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg. 2019;14:8. doi:10.1186/s13017-019-0228-3.

Sartelli M, Malangoni MA, Abu-Zidan FM, et al. WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg. 2015;10:38. doi:10.1186/s13017-015-0033-6.

Goncharik II, Tsarev VP, Malaia TV. Psevdomembranoznyi kolit. Voennaia meditsina. 2010;(16):112-116. (in Russian).

Chyornenkaya TV. Pseudomembranous colitis: diagnosis, treatment and prevention (literature review). Sklifosovsky Journal of Emergency Medical Care. 2016;(1):33-39. (in Russian).

Sheptulin АА. Refractory and recurrent forms of colitis associated with Clostridium difficile. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2011;21(2):50-53. (in Russian).

Safdar N, Henderson S. Clostridium Difficile Infection: Prevention, Diagnosis And Treatment. Adult/Pediatric - Inpatient/Ambulatory/Emergency Department Clinical Practice Guideline. Madison, WI: UWHealth; 2018. 29 p.

Mullish BH, Williams HR. Clostridium difficile infection and antibiotic-associated diarrhoea. Clin Med (Lond). 2018;18(3):237-241. doi:10.7861/clinmedicine.18-3-237.

Aberra FN, Anand BS. Clostridioides (Clostridium) Difficile Colitis. Available from: https://emedicine.medscape.com/article/186458-overview. Accessed: July 25, 2019.

Ivashkin VT, Yushchuk ND, Mayev IV, et al. Diagnostics and treatment of Clostridium difficile-associated disease: guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(5):56-65. (in Russian).

Shelygin IuA, Aleshkin VA, Sukhina MA, et al. Klinicheskie rekomendatsii Natsional'noi assotsiatsii spetsialistov po kontroliu infektsii, sviazannykh s okazaniem meditsinskoi pomoshchi i Obshcherossiiskoi obshchestvennoi nekommercheskoi organizatsii Aassotsiatsiia koloproktologov Rossii po diagnostike, lecheniiu i profilaktike Klostridium Difficile-assotsiirovannoi diarei (CDI) [Clinical guidelines of the National Association of Specialists in the Control of Infections Associated with the Provision of Medical Care and the All-Russian Public Non-Profit Organization Association of Coloproctologists of Russia for the Diagnosis, Treatment and Prevention of Clostridium Difficile-Associated Diarrhea (CDI)]. Moscow; 2017. 51 p. (in Russian).

Guery B, Galperine T, Barbut F. Clostridioides difficile: diagnosis and treatments. BMJ. 2019;366:l4609. doi:10.1136/bmj.l4609.

Curcio D, Cané A, Fernández FA, Correa J. Clostridium difficile-associated Diarrhea in Developing Countries: A Systematic Review and Meta-Analysis. Infect Dis Ther. 2019;8(1):87-103. doi:10.1007/s40121-019-0231-8.

Vindigni SM, Surawicz CM. C. difficile Infection: Changing Epidemiology and Management Paradigms. Clin Transl Gastroenterol. 2015;6(7):e99. doi:10.1038/ctg.2015.24.

Safin AL, Achkasov SI, Sukhina MA, Sushkov OI. Risk factors for diarrhea associated with Сlostridium difficile in coloproctological patients (review). Koloproktologia. 2017;(59):59-67. doi:10.33878/2073-7556-2017-0-1-59-67. (in Russian).

Kazanowski M, Smolarek S, Kinnarney F, Grzebieniak Z. Clostridium difficile: epidemiology, diagnostic and therapeutic possibilities-a systematic review. Tech Coloproctol. 2014;18(3):223-232. doi:10.1007/s10151-013-1081-0.

Linsenmeyer K, O'Brien W, Brecher SM, et al. Clostridium difficile Screening for Colonization During an Outbreak Setting. Clin Infect Dis. 2018;67(12):1912-1914. doi:10.1093/cid/ciy455.

Lawley TD, Croucher NJ, Yu L, et al. Proteomic and genomic characterization of highly infectious Clostridium difficile 630 spores. J Bacteriol. 2009;191(17):5377-5386. doi:10.1128/JB.00597-09.

Schenck LP, Beck PL, MacDonald JA. Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection. World J Gastrointest Pathophysiol. 2015;6(4):169-180. doi:10.4291/wjgp.v6.i4.169.

Beer LA, Tatge H, Schneider C, et al. The Binary Toxin CDT of Clostridium difficile as a Tool for Intracellular Delivery of Bacterial Glucosyltransferase Domains. Toxins (Basel). 2018;10(6):225. doi:10.3390/toxins10060225.

Crobach MJ, Planche T, Eckert C, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016;22 Suppl 4:S63-S81. doi:10.1016/j.cmi.2016.03.010.

De Rosa FG, Cavallerio P, Corcione S, et al. Molecular characterization of toxigenic Clostridium difficile in a northern Italian hospital. Curr Microbiol. 2015;70(2):154-155. doi:10.1007/s00284-014-0690-9.

Di Bella S, Ascenzi P, Siarakas S, Petrosillo N, di Masi A. Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects. Toxins (Basel). 2016;8(5):134. doi:10.3390/toxins8050134.

Kuehne SA, Collery MM, Kelly ML, Cartman ST, Cockayne A, Minton NP. Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain. J Infect Dis. 2014;209(1):83-86. doi:10.1093/infdis/jit426.

McFarland LV. Renewed interest in a difficult disease: Clostridium difficile infections--epidemiology and current treatment strategies. Curr Opin Gastroenterol. 2009;25(1):24-35. doi:10.1097/MOG.0b013e32831da7c4.

Howerton A, Ramirez N, Abel-Santos E. Mapping interactions between germinants and Clostridium difficile spores. J Bacteriol. 2011;193(1):274-282. doi:10.1128/JB.00980-10.

Oldfield EC IV, Oldfield EC III, Johnson DA. Clinical update for the diagnosis and treatment of Clostridium difficile infection. World J Gastrointest Pharmacol Ther. 2014;5(1):1-26. doi:10.4292/wjgpt.v5.i1.1.

Kociolek LK, Gerding DN. Clinical Utility of Laboratory Detection of Clostridium difficile Strain BI/NAP1/027. J Clin Microbiol. 2016;54(1):19-24. doi:10.1128/JCM.02340-15.

Adams SD, Mercer DW. Fulminant Clostridium difficile colitis. Curr Opin Crit Care. 2007;13(4):450-455. doi:10.1097/MCC.0b013e3282638879.

LaBarbera FD, Nikiforov I, Parvathenani A, Pramil V, Gorrepati S. A prediction model for Clostridium difficile recurrence. J Community Hosp Intern Med Perspect. 2015;5(1):26033. doi:10.3402/jchimp.v5.26033.

Petrosillo N. Tackling the recurrence of Clostridium difficile infection. Med Mal Infect. 2018;48(1):18-22. doi:10.1016/j.medmal.2017.10.007.

Sheitoyan-Pesant C, Abou Chakra CN, Pépin J, Marcil-Héguy A, Nault V, Valiquette L. Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection. Clin Infect Dis. 2016;62(5):574-580. doi:10.1093/cid/civ958.

Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18 Suppl 6:21-27. doi:10.1111/1469-0691.12046.

Samie AA, Traub M, Bachmann K, Kopischke K, Theilmann L. Risk factors for recurrence of Clostridium difficile-associated diarrhoea. Hepatogastroenterology. 2013;60(126):1351-1354. doi:10.5754/hge12588.

Holler JG, Henriksen DP, Mikkelsen S, Rasmussen LM, Pedersen C, Lassen AT. Erratum to: Shock in the emergency department; a 12 year population based cohort study. Scand J Trauma Resusc Emerg Med. 2017;25(1):103. doi:10.1186/s13049-017-0429-2.

Bulloch M. New Treatment Guidelines for Clostridium Difficile. Available from: https://www.pharmacytimes.com/contributor/marilyn-bulloch-pharmd-bcps/2018/02/new-treatment-guidelines-for-clostridium-difficile. Accessed: February 16, 2018.

Cao F, Chen CX, Wang M, et al. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection. J Hosp Infect. 2018;98(1):4-13. doi:10.1016/j.jhin.2017.08.017.

Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48(8):693-702. doi:10.1097/MCG.0000000000000046.

Shah DN, Aitken SL, Barragan LF, et al. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect. 2016;93(3):286-289. doi:10.1016/j.jhin.2016.04.004.

Farooq PD, Urrunaga NH, Tang DM, von Rosenvinge EC. Pseudomembranous colitis. Dis Mon. 2015;61(5):181-206. doi:10.1016/j.disamonth.2015.01.006.

Diorio C, Robinson PD, Ammann RA, et al. Guideline for the Management of Clostridium Difficile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients. J Clin Oncol. 2018;36(31):3162-3171. doi:10.1200/JCO.18.00407.

Published

2021-09-06

How to Cite

Stepanov, Y., Simonova, E., Budzak, I., & Коnonov I. (2021). Clostridium difficile-associated colitis: literature review, case report. GASTROENTEROLOGY, 54(3), 188–201. https://doi.org/10.22141/2308-2097.54.3.2020.211739

Issue

Section

Reviews and Lections